Table 1 Patient characteristics.
Characteristics | Number of patients (%) | ||
|---|---|---|---|
| Â | Total (91) | GBC (71) | GBM (20) |
Age in years (median, range) | 39 (18–64) | 38 (18–64) | 45 (18–57) |
 <60 | 88 (96.7) | 68 (95.8) | 20 (100) |
 ≥60 | 3 (3.3) | 3 (4.2) | 0 |
Sex | |||
  Male | 51 (56.0) | 39 (54.9) | 12 (60.0) |
  Female | 40 (44.0) | 32 (45.1) | 8 (40.0) |
ECOG | |||
  0–1 | 73(80.2) | 54 (76.1) | 20 (100) |
  >2 | 18 (19.8) | 17 (23.9) | 0 (0) |
Histology | |||
  LBCL | 42 (46.2) | 33 (46.5) | 9 (45.0) |
  MCL | 16 (17.6) | 9 (12.7) | 7 (35.0) |
  HL | 12 (13.2) | 9 (12.7) | 3 (15.0) |
  FL | 6 (6.6) | 6 (8.4) | 0 |
  Burkitt lymphoma | 2 (2.2) | 2 (2.8) | 0 |
  PTCL or NK/T lymphoma | 12 (13.1) | 11 (15.5) | 1 (5.0) |
  Plasmablastic lymphoma | 1 (1.1) | 1 (1.4) | 0 |
IPI risk group of LBCL | |||
  Low (0–1) | 15 (35.7) | 13 (39.4) | 2 (22.2) |
  Low–Intermediate (2) | 10 (23.8) | 6 (18.2) | 4 (44.4) |
  High-Intermediate (3) | 13 (31.0) | 10 (30.3) | 3 (33.4) |
  High (4–5) | 4 (9.5) | 4 (12.1) | 0 |
Ann Arbor stage | |||
  I | 4 (4.4) | 4 (5.6) | 0 |
  II | 13 (14.3) | 10 (14.1) | 3 (15.0) |
  III | 25 (27.5) | 20 (28.2) | 5 (25.0) |
  IV | 49 (53.8) | 37 (52.1) | 12 (60.0) |
 Bone marrow involvement | 32 (35.2) | 26 (36.6) | 6 (30.0) |
 Extra-nodal involvement | 47 (51.6) | 35 (49.3) | 12 (60.0) |
 B symptoms | 23 (25.3) | 18 (25.4) | 5 (25.0) |
 TP53 or deletion | 15 (16.5) | 13 (18.3) | 2 (10.0) |
Number of prior chemotherapies | |||
  1 | 64 (70.3) | 53 (74.6) | 11 (55.0) |
  ≥2 | 27 (29.7) | 18 (25.4) | 9 (45.0) |
Status before ASCT | |||
  CR | 76 (83.5) | 60 (84.5) | 16 (80.0) |
  CR1 | 55 (60.4) | 47 (66.2) | 8 (40.0) |
  Not in CR1 | 21 (23.1) | 13 (18.3) | 8 (40.0) |
  PR | 14 (15.4) | 10 (14.1) | 4 (20.0) |
  PR1 | 9 (9.9) | 6 (8.5) | 3 (15.0) |
  Not in PR1 | 5 (5.5) | 4 (5.6) | 1 (5.0) |
  SD2 | 1 (1.1) | 1 (1.4) | 0 |
